Brisbane, Australia – August 13, 2025 - Ketim Technologies is proud to announce that Founder and CEO, Dr. Clarissa Yates, Ph.D., has been named a finalist in the prestigious Women in Technology (WiT) 2025 Future Focused Business Achiever Award. This recognition celebrates entrepreneurs and teams who are driving purposeful innovation to create a stronger future.

Brisbane, Australia – July 31, 2025 – Ketim Therapeutics, a leading innovator in perinatal mental health diagnostics, is proud to share that Founder and CEO, Dr. Clarissa Yates, Ph.D., was a featured speaker at the Innovation in Women’s Health event hosted by HealthTech Innovation QLD and FB Rice. The panel brought together academics, clinicians, founders, and industry leaders to discuss advancing women’s health through science, entrepreneurship, and advocacy.

Brisbane, Australia – July 29, 2025 – Ketim Therapeutics, a leader in biomarker-based diagnostics for perinatal mental health, is proud to announce its selection for the Year 4 Cohort of the Brisbane Economic Development Agency’s (BEDA) MedTech Global Accelerator Program.

Brisbane, Australia – 15 July 2025 – Ketim Technologies has been named the winner of the Start-Up category at the Queensland iAwards, one of Australia’s most recognised technology innovation programs. The award honours the company’s groundbreaking work in developing biomarker-based, AI-powered diagnostics for the early detection of postpartum depression (PPD).

Brisbane, Australia – July 15, 2025 – Ketim Technologies has been named a nominee for the Queensland iAwards, one of Australia’s most prestigious technology innovation programs. The recognition acknowledges the company’s pioneering work in developing biomarker-based, AI-powered diagnostics for the early detection of postpartum depression (PPD).

Brisbane, Australia – July 11, 2025 – Ketim Technologies has received its first shipment of dried blood spot (DBS) collection devices from Swedish partner Capitainer, marking a major step forward in the company’s mission to expand access to early detection of postpartum depression (PPD).

Brisbane, Australia – June 7, 2025 – Ketim Technologies has been named a semi-finalist in the Female Led Start-Up category of the 2025 Australian Technologies Competition (ATC), Australia’s premier technology awards program.

Sydney, Australia – May 8, 2025 – Ketim Technologies, a leader in biomarker-based diagnostics for perinatal mental health, was proud to present at the BioInnovation Spotlight during AusMedTech 2025, Australia’s premier medical technology conference hosted by AusBiotech.

Brisbane, Australia – April 24, 2025 – Ketim Technologies has made significant strides in its mission to transform maternal mental health care, securing two grants totalling $2.25 million and delivering six investor pitches across Queensland, with two more scheduled interstate as part of its current $1 million raise.

Brisbane, Australia – April 16, 2025 – Ketim Technologies, a leader in biomarker-based diagnostics for perinatal mental health, has marked its first anniversary with significant scientific progress and growing investor interest in its pioneering approach to early detection of postpartum depression (PPD).

Brisbane, Australia – April 3, 2025 – Ketim Technologies, a leader in biomarker-based diagnostics for perinatal mental health, has been selected to join AusBiotech’s inaugural Innovation Activation Program, delivered as part of the Australian Government’s Industry Growth Program.

Brisbane, Australia – March 21, 2025 – Ketim Technologies, a pioneer in biomarker-based diagnostics for perinatal mental health, is proud to share that Founder and CEO, Dr. Clarissa Yates, Ph.D., presented at the Power Up Your Multi-Omic Discoveries | Next Gen Olink® Proteomics seminar, hosted by the Australian Genome Research Facility (AGRF Ltd) at the Translational Research Institute, Brisbane.

Brisbane, Australia – March 16, 2025 – Ketim Technologies, a leader in biomarker-based diagnostics for perinatal mental health, is proud to share that Founder and CEO, Dr. Clarissa Yates, Ph.D., participated as a panelist at the Perinatal Society of Australia and New Zealand (PSANZ) 2025 Breakfast Symposium, Beyond Birth: Compassionate Care after Birth Trauma and its Relationship with Mental Health Care.

Brisbane, Australia – March 5, 2025 – Ketim Technologies, a leader in biomarker-based diagnostics for perinatal mental health, is proud to recognise Founder and CEO, Dr. Clarissa Yates, Ph.D., for her role as a featured panelist at Tech Ready Women Academy’s International Women’s Day event, An Evening with Christie Whitehill: Breaking Barriers in Capital Raising.

Brisbane, Australia – Feb 20, 2025 – Ketim Technologies, a leader in biomarker-based diagnostics for perinatal mental health, is proud to announce it has been granted provisional approval as a commercial entity to collaborate with The Kids Research Institute in Western Australia and access the ORIGINS Birth Cohort Biobank.

Ketim Therapeutics Announces New Advisory Board Member, Dr. Scott Fry, Ph.D.

Ketim Therapeutics is thrilled to welcome Dr. Scott Fry, Ph.D., to its Advisory Board. With extensive expertise in diagnostics and biotechnology, Dr. Fry’s career highlights include leading the successful launch of the first over-the-counter COVID-19 diagnostic test in the United States as Chief Operations Officer at Ellume Limited. His experience in scaling diagnostic solutions, including ELISAs for detecting various diseases, aligns perfectly with Ketim’s mission to transform perinatal mental health care.

“Dr. Fry’s strategic insights and vast experience will help us drive innovation and deliver impactful solutions for women’s health,” said Dr. Clarissa Yates, CEO of Ketim Therapeutics.